Biography
Dr Mark Nalder is a highly experienced and compassionate medical oncologist dedicated to delivering high-quality, personalised cancer care. With a strong focus on communication, he ensures that patients and their families feel informed, involved, and supported throughout their treatment.
Dr Mark Nalder is an experienced medical oncologist at Icon Cancer Centre. He provides consultation services at the Icon Cancer Centre consultation rooms located at St Vincent’s Private Hospital Northside and at Icon Cancer Centre Chermside, with treatment available at both locations.
Dr Nalder holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) and Bachelor of Behavioural Science in Psychology (BBehavSc(Psych)). He completed his physician and specialist medical oncology training at various hospitals throughout Queensland before undertaking a clinical research fellowship at the Royal Brisbane and Women’s Hospital.
During his fellowship, Dr Nalder led a multi-institutional genomics trial aimed at reducing the toxicity of chemotherapy. His research collaborations extend to the Queensland Cancer Alliance and The University of Queensland’s Centre for Health Services Research, focusing on immunotherapy treatment outcomes in Queensland.
He is actively involved in research as a Principal Investigator and co-Investigator on numerous clinical trials and member of several Australian collaborative research groups. His work has been recognised both nationally and internationally, with presentations at leading conferences and forums.
Alongside his practice at Icon, Dr Nalder is a Medical Oncology Staff Specialist at the Royal Brisbane and Women’s Hospital, and consults and treats patients at St Vincent’s Private Hospital, Northside. He is also a Lecturer at The University of Queensland, where he actively contributes to the education of medical students and oncology trainees across Queensland.
Dr Nalder’s clinical experience covers a wide range of solid tumour malignancies, with a special interest in gastrointestinal, skin, lung and urological cancers.
Publications
White, C., Wardill, H., Nalder, M., et.al. (2024). DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol. BMC cancer, 24(1), 1369.
Nalder, M., Kulasegaran, T., Lundie, B., (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. Journal of Clinical Oncology, 41(16).
Reed, A., McCurry, T., Nalder, M., et. al. (2023). The Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study. Medical Journal of Australia.
Nalder, M., Eastgate, M., Wyld, D. & Burge, M. (2022). Clinical implementation of routine, prospective DPYD genotyping in patients receiving fluoropyrimidine chemotherapy: Feasibility and prevalence from a multi-site study. Asia-Pacific Journal of Clinical Oncology (18), 28-19.
Hansoo, K., Tivya, K., Nalder, M., et.al. (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. Asia-Pacific Journal of Clinical Oncology (18).